Literature DB >> 22233694

Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?

Lena Ohman1, Mats Stridsberg, Stefan Isaksson, Pernilla Jerlstad, Magnus Simrén.   

Abstract

OBJECTIVES: Chromogranins (Cg) and secretogranins (Sg) are proteins ubiquitous in secretory cells of the enteric, endocrine, and immune systems, and may reflect activity of these systems. We therefore performed a hypothesis generating study to evaluate the association between fecal levels of CgA, CgB, SgII, and SgIII, with the clinical and pathophysiological phenotype of irritable bowel syndrome (IBS) patients.
METHODS: Analyses of CgA, CgB, SgII, SgIII, and calprotectin in fecal samples of 82 IBS patients and 29 healthy controls were performed. All IBS subjects completed validated questionnaires to assess gastrointestinal and psychological symptom severity, and underwent rectal barostat test and colonic transit time measurement.
RESULTS: IBS patients demonstrated higher levels of fecal CgA (P=0.009), SgII (P<0.001), and SgIII (P<0.001), but lower levels of CgB (P<0.001) compared with controls. SgII had good discriminative validity to positively identify IBS patients, with an area under the receiver operating characteristics (ROC) curve (AUROC) of 0.86 (95% confidence interval (CI): 0.78-0.94). SgIII and CgB both had fairly good discriminative validity to positively identify IBS patients, with an AUROC of 0.79 (95% CI: 0.71-0.87) and 0.78 (95% CI: 0.69-0.87), respectively. There were negative correlations between the colonic transit time and fecal levels of CgA (r=-0.53, P<0.001), SgII (r=-0.55, P<0.001), and SgIII (r=-0.28, P=0.03). Perceived abdominal pain was moderately associated with levels of CgA (r=0.32, P=0.004), SgII (r=0.31, P=0.006), and SgIII (r=0.24, P=0.04). Calprotectin levels were not associated with the levels of granins or with the clinical or pathophysiological phenotype of IBS patients.
CONCLUSIONS: Fecal levels of Cg and Sg may be related to the underlying pathophysiology of IBS and of potential importance for symptoms of the patients. Granins also show promise to serve as future biomarkers of IBS. Further studies are needed to explore the potential role of granins in IBS patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233694     DOI: 10.1038/ajg.2011.458

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  27 in total

1.  Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-04-30       Impact factor: 4.052

2.  RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio; Asha A Nair; Simon J Gibbons; Gianrico Farrugia; Eric W Klee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-24       Impact factor: 4.052

Review 3.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 4.  Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea.

Authors:  Michael Camilleri; Joseph H Sellin; Kim E Barrett
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

5.  Editorial: fecal granins in IBS: cause or indicator of intestinal or colonic irritation?

Authors:  Michael Camilleri
Journal:  Am J Gastroenterol       Date:  2012-03       Impact factor: 10.864

Review 6.  Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea.

Authors:  Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-17       Impact factor: 11.382

7.  Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea.

Authors:  Michael Camilleri; Paula Carlson; Nelson Valentin; Andres Acosta; Jessica O'Neill; Deborah Eckert; Roy Dyer; Jie Na; Eric W Klee; Joseph A Murray
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-21       Impact factor: 4.052

Review 8.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 9.  Refractory inflammatory bowel disease-could it be an irritable bowel?

Authors:  Jie Meng; Anurag Agrawal; Peter J Whorwell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-09-11       Impact factor: 46.802

10.  Pain self-management plus nurse-led support in young adults with irritable bowel syndrome: Study protocol for a pilot randomized control trial.

Authors:  Xiaomei Cong; Divya Ramesh; Mallory Perry; Wanli Xu; Katherine M Bernier; Erin E Young; Stephen Walsh; Angela Starkweather
Journal:  Res Nurs Health       Date:  2018-02-01       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.